Explore a multidisciplinary, patient-centered approach to first-line CLL care at The Ohio State University Comprehensive Cancer Center – The James, where active surveillance, shared decision-making, and clinical trial access guide treatment.
Navigate treatment decisions after covalent Bruton’s tyrosine kinase (BTK) inhibitor therapy with this evidence-based resource for CLL care. Receive clear guidance to distinguish progression from intolerance, optimizing next-line therapy selection.
This patient journey tool outlines best practices for patient-centered CLL care from diagnosis through treatment initiation. Download strategies for aligning clinical processes with patient goals, preferences, and supportive care needs.
Explore practical, patient-centered first-line CLL treatment strategies. Download this tip sheet for actionable guidance on explaining treatment options, eliciting patient preferences, and navigating clinical trial discussions.
Discover evolving CLL treatment options, strategies for optimizing therapy selection and sequencing, and approaches to managing adverse events for improved patient outcomes.
Managing chronic lymphocytic leukemia (CLL) after double exposure to Bruton’s tyrosine kinase (BTK) and B-cell leukemia/lymphoma 2 (BCL2) inhibitors requires a tailored approach. This guide provides considerations and strategies to optimize outcomes for these patients.
ACCC’s Effective Practice Guide highlights case studies profiling effective practices in the integration of oral oncolytics into the cancer continuum. The case studies outline key roles, address specific challenges, and discuss current solutions and plans for oral oncolytic integration.
This 6-part video series explores how innovation, equity, and patient-centered approaches are shaping the future of chronic lymphocytic leukemia (CLL) care. Through expert perspectives and real-world insights, viewers will gain a broader understanding of evolving strategies that aim to improve access, quality, and outcomes across the CLL care continuum.